Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.
-
Upload
isaac-floyd -
Category
Documents
-
view
214 -
download
0
Transcript of Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.
![Page 1: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/1.jpg)
Cord Blood vs. Unrelated DonorTransplantation
Elizabeth J. Shpall, MD
•
![Page 2: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/2.jpg)
Allogeneic Marrow TransplantationTreatment of choice for selected high-risk patients
with:
• Acute Leukemia (ALL, AML)• Chronic Leukemia (CML, CLL)• Follicular Lymphomas• Aplastic Anemia• Several Genetic and Immunologic Diseases
Less than 30% of patients have a related donor
Increasing use of unrelated and cord blood donors
![Page 3: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/3.jpg)
Potential Advantages of Cord Blood
• Procurement non-invasive
• Expanded donor pool: minorities targeted
• Immediate availability (overnight shipping)
• Requires less stringent HLA matching (4/6, 5/6)
• Less GVHD than marrow transplants
![Page 4: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/4.jpg)
NMDPTransplants by Cell Source1988–2010
4
![Page 5: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/5.jpg)
N=3038Bone marrow Peripheral bloodTransplantsYear 1980 - 2003
N=280Cord blood transplantsYear 1996 - 2010
59%
25%
M. D. Anderson BMT Department Minority Allo-transplants by Stem Cell Source
![Page 6: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/6.jpg)
Rocha, V. et al. N Engl J Med 2004;351:2276-2285
Outcomes after Transplantation of Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia
Eurocord data compared to EBMTR data on MUD bone marrow transplants
Cord blood n = 98
Bone marrow n = 584
HLA matching
Cord blood: 94% with at least one mismatch
Bone marrow: 100% matched
Median cell dose
Cord blood: 0.23 x 108
Bone marrow: 2.9 x 108
![Page 7: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/7.jpg)
Adult Single Myeloablative CB
Investigator N Disease DFS
Ooi 77 AML 63%
Sanz 49 AML 42%
Verneris 84 ALL/AML 40%
Rodrigues 78 lymphoma 36%
![Page 8: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/8.jpg)
Myeloablative CBTFor AML/ ALL
(CR1/ 2): Survival
Years
Pro
bab
ilit
y
p = 0.16
0.0
0.2
0.4
0.6
0.8
1.0
0 1 2 3
II
I I II
I I II
I III
IIII I I I II I I II I I I III
Doubles (n = 29) 72% (56 - 88%)
Singles (n = 67) 47% (51-75%)
Verneris et al, Blood 2005, 106; 93a
Months
p = 0.05
0.0
0.2
0.4
0.6
0.8
1.0
0 4 8 12 16 20 24
Double 9% (0 - 21%)
Single 30% (16 - 44%)
Relapse
![Page 9: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/9.jpg)
Non-Myeloablative Conditioning
Fludarabine 30 mg/m2/d ATG 1.5 mg/kg/d Melphalan 100 mg/m2/d
Day -8 -7 -6 -5 -4 -3 -2 -1 0
Fludarabine
ATG
Melphalan
TacrolimusSirolimus
DUCBT
1-6 hrs
Tacrolimus
Day -8 -7 -6 -5 -4 -3 -2 -1 0
Fludarabine
ATG
Melphalan
TacrolimusSirolimus
DUCBT
1-6 hrs
Day -8 -7 -6 -5 -4 -3 -2 -1 0
Fludarabine
ATG
Melphalan
TacrolimusSirolimus
DUCBT
1-6 hrs
DUCBT
1-6 hrs
Tacrolimus TacrolimusTacrolimusSirolimusTacrolimus
MMFCyclosporine
![Page 10: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/10.jpg)
Promising Overall Survival after Nonmyeloablative CB Transplantation
Years
Cum
ulati
ve P
ropo
rtion
0.0
0.2
0.4
0.6
0.8
1.0
0 1 2 3 4 5
IIIIIIII
I III II IIII I I II I I I III II IIIIII I II I
I IIII IIIII II I II I I II II I I II II I I II II I I II I IIIII
45% (95%CI 36-54)
Brunstein et al. Blood 2007
![Page 11: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/11.jpg)
Methods-Eapen et al
• Explored whether there were survival differences by conditioning regimen within each graft source:
– survival after dCB with TBI200/Cy/Flu ± ATG vs. dCB with other regimens
– No differences in the PB group
• Therefore 4 treatment groups were created:
– MUD (8/8 allele matched unrelated donor)
– MMUD (7/8 allele matched unrelated donor)
– dCB, TCF
– dCB, other
![Page 12: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/12.jpg)
Patient CharacteristicsVariables MUD MMUD
dCB, TCF
dCB, other
P-value
Number of patients 313 111 121 40
Median age (years) 59 58 55 48 <0.0001
CMV Seropositive 56 % 60% 68 % 78 % 0.021
Performance score < 90% 39% 40% 27% 43% 0.036
Year of transplant 2000-2004 31% 26% 21% 8% 0.0061
2005-2009 69% 74% 79% 92%
Median follow-up of survivors (months)
35 25 25 25
![Page 13: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/13.jpg)
Disease Characteristics
Variables MUD MMUDdCB, TCF
dCB, other P-value
Number of patients 313 111 121 40
AML 94% 90% 82% 75% <0.0001
ALL 6% 10% 18% 25%
CR1 53% 48% 61% 25% <0.0001
CR2 21% 17% 27% 43%
CR3+ 3% 5% 6% 5%
PIF, relapse 24% 30% 6% 28%
![Page 14: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/14.jpg)
Conditioning Regimens
VariablesMUD MMUD
dCB, TCF
dCB, other
P-value
Number of patients 313 111 121 40
TBI + CY + FLU ± ATG 0 0 100% 0 <0.0001
TBI + FLU ± ATG 24% 18% 0 5% TBI + FLU + BU ± ATG 3% 5% 0 15%
BU + FLU ± ATG 38% 41% 0 5%
MEL+ FLU ± ATG 27% 27% 0 70%
CY + FLU ± ATG 8% 9% 0 5%
![Page 15: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/15.jpg)
Neutrophil Recovery
Fk10_54.ppt
Cum
ulat
ive
Inci
denc
e, %
Days
0 7 14 422821
100
0
20
40
60
80
90
10
30
50
70
0
100
20
40
60
80
90
10
30
50
70
35
MMUD: 95%
MUD: 96%
P=0.0007
dCB, TCF: 83%
dCB, other: 83%
![Page 16: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/16.jpg)
Platelet RecoveryC
umul
ativ
e In
cide
nce,
%
Months
0 1 2 643
100
0
20
40
60
80
90
10
30
50
70
0
100
20
40
60
80
90
10
30
50
70
Fk10_53.ppt
5
MMUD: 89%
MUD: 90%
dCB, TCF: 66%
dCB, other: 58%
P <0.0001
![Page 17: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/17.jpg)
Grade 3-4 Acute GVHDC
umul
ativ
e In
cide
nce,
%
Months
0 1 2 643
100
0
20
40
60
80
90
10
30
50
70
0
100
20
40
60
80
90
10
30
50
70
Fk10_51.ppt
5
MMUD: 22%
MUD: 13%
dCB, TCF: 17%
dCB, other: 18%
P=NS
![Page 18: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/18.jpg)
Chronic Graft vs. Host DiseaseC
umul
ativ
e In
cide
nce,
%
Months
0 6 12 362418
100
0
20
40
60
80
90
10
30
50
70
0
100
20
40
60
80
90
10
30
50
70
Fk10_50.ppt
30
MMUD: 54%
MUD: 56%
dCB, TCF: 34%
dCB, other: 36%
P<0.0001
![Page 19: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/19.jpg)
Leukemia-Free SurvivalP
roba
bilit
y, %
Months
0 6 12 362418
100
0
20
40
60
80
90
10
30
50
70
0
100
20
40
60
80
90
10
30
50
70
Fk10_49.ppt
30
MMUD: 25%
MUD: 31%
dCB, TCF: 26%
dCB, other: 9%
P=0.017MUD vs. dCB other 0.68 (0.47 – 0.99) 0.046
![Page 20: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/20.jpg)
N=536CBT 128MRD 204MUD 152MMUD 52
P=NSP<0.01
MRD p<0.01MUD p=0.13MMUD p<0.01
Double CBT LFS is comparable to MRD and MUDFred Hutchison Ca Center and Univ Minnesota
Brunstein and Delaney, Blood 2010
![Page 21: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/21.jpg)
• Low Cell Dose• Delayed Engraftment• Delayed Immune Reconstitution • Increased Graft Failure
Disadvantages of Cord Blood vs. Bone Marrow or Peripheral Blood Progenitor Cell (PBPC)
Transplantation
PBPC remains the “gold standard” against which performance of CB compared:
• Neutrophil engraftment (>500/µl) 11 days• Platelets engraftment (>20,000/µl) 13 days• Engraftment failure rate <1%
![Page 22: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/22.jpg)
Mesenchymal Stem Cells (MSC)
• MSC are a stromal componentof the hematopoietic microenvironment.
• They provide cellular and extracellular components of the stem cell “niche”.
• When isolated and used in vitro
in combination with cytokines, MSC markedly increase the expansion of CB hematopoietic progenitors.
![Page 23: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/23.jpg)
Day 1- 7 co-culture
SCFG-CSFFlt-3LTPO
T150
Day 14: Non-
adherent cells washed and infused
1 liter
Day 7-14 culture
FrozenCB unit
CB MNCthawed
and washed
14 day ex vivo expansion culture
10 bags
10 flasks
M. D. Anderson CB Expansion Trial with“off-the-shelf” Angioblast MPC (N=24)
4 days
Single vial ofAngioblast MSC
+
![Page 24: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/24.jpg)
Day 0Infuse unmanipulated CB (CB#2)
ANDEx vivo expanded CB (CB#1)
Day –8 to –2 High-Dose TherapyG-CSF
Thaw & washunmanipulated CB
(CB#2)
Day -14Thaw &
wash CB#1
Ex vivo CB#1-MSC co-culture expansion for 14 days
0
Day 0Infuse unmanipulated CB (CB#2)
ANDEx vivo expanded CB (CB#1)
Day –8 to –2 High-Dose TherapyG-CSF
Thaw & washunmanipulated CB
(CB#2)
Day -14Thaw &
wash CB#1
Ex vivo CB#1-MSC co-culture expansion for 14 days
0
Day Preparative regimen -9 Hydration Therapy
-8 Melphalan 140 mg/m2
-7 Thiotepa 10 mg / Kg
-6 Fludarabine 40 mg/m2
-5 Fludarabine 40 mg/m2
-4 Fludarabine 40 mg/m2 Rabbit-ATG
-3 Fludarabine 40 mg/m2 Rabbit-ATG
-2 Rest
-1 Rest
0 CB Infusions
MSC-CB Expansion Trial
GvHD Prophylaxis:Tacrolimus and MMF
Day 0Infuse unmanipulated CB unit
ANDEx vivo expanded CB unit
![Page 25: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/25.jpg)
Median time to engraftment (range)
Neutrophil (>500/µl) 15 days (range 9-42)Platelet (>20,000/µl)40 days (range 13-62)
Cumulative Incidence of Engraftment
Neutrophil (>500/µl) 97% (n=31)Platelet (>20,000/µl) 81% (n=26)
- One patient died before engraftment
MSC-CB Expansion Trial Engraftment Data
de Lima et al. Blood (ASH Annual Meeting Abstracts), 2010; 116: 362
![Page 26: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/26.jpg)
0
20
40
60
80
100
0 6 12 18 24 30 36 42
Days after Transplant
Cu
mu
lativ
e In
cid
en
ce (
%)
CIBMTR (@26 days, 53%, N=80)
Angioblast(@26 days, 88%, N=24)
@26 daysP<0.0001
M. Horowitz et al.
Cumulative Incidence of Neutrophil Recovery
![Page 27: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/27.jpg)
0
20
40
60
80
100
0 6 12 18 24 30 36 42 48 54 60
Days after Transplant
Cu
mu
lativ
e In
cid
en
ce (
%)
CIBMTR(@60 days, 31%, N=80)
Angioblast (@60 days, 67%, N=24)
@26 daysP=0.0008
M. Horowitz et al.
Cumulative Incidence of Platelet Recovery
![Page 28: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/28.jpg)
Obstacles to Successful Outcomes after
Cord Blood Transplantation: GVHD
Potential Solution:• Cord Blood Regulatory T cells (Tregs) co-
expressing CD4/CD25 have been shown to inhibit alloreactive T cell function
• We hypothesized that prophylactic infusion of 3rd party CB Tregs would abrogate GVHD
![Page 29: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/29.jpg)
CD4+25+ CB cells isolated magnetically and cultured with IL2
and• Xcyte Bead CD3/28 co-expression (cell:
bead=1:3) or• Clone 4 K562-APCs (cell:bead=1:4)
APC
CD64
OKT3 IL-15
CD187c
CD86
CD69
Parmar et al.
![Page 30: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/30.jpg)
Expanded CD25+ cells show phenotype consistent with Tregs
![Page 31: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/31.jpg)
Ex vivo expanded CB Tregs reduce GVHD and enhance survival in mice
Treg+PBMC
PBMC alonep < 10-4
Days post Transplant
Log rank test
0
1
2
3
4
AV. GVHD score
PBMC ONLY
PBMC + Treg
Parmar et al.
![Page 32: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/32.jpg)
Recipients of Tregs do not show signs of GVHD – Parmar et al.
NO Treg WITH Treg NO Treg WITH Treg
LUN
GLI
VE
R
A clinical trial with CB Tregs is being designed
![Page 33: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/33.jpg)
Obstacles to Successful Outcomes after
Cord Blood Transplantation: Relapse
• Large granular lymphocytes, comprising 10-15% of all peripheral blood lymphocytes
• CD56+CD3-
• Have the ability to directly kill target cells in an MHC-independent manner
• GVL without GVH
![Page 34: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/34.jpg)
Potential Solution:Expansion of CB-NK cells
1
10
100
1000
10000
CD56+ alone Frozen cord, APC Fresh cord, APC
Nina Shah et al
![Page 35: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/35.jpg)
CB-derived NK Cells can kill Primary CLL
Cells in vitro – Bollard Laboratory
![Page 36: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/36.jpg)
-3 -2 -1-4-6 -5 30 1000
Specific cell populations will be generated in the GMP Lab:
Future Directions: Cord Blood Transplantation in the Next 5 Years
Viral-TumorSpecificCB T cells
MSC-Expansion +/- FTVI for neut and plat engraftment Adeno
CMVEBV
Tumor-SpecificCB NK cells
B Cell MyeloidTumors
CB#1 CB#2
CB Tregs
![Page 37: Cord Blood vs. Unrelated Donor Transplantation Elizabeth J. Shpall, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062516/56649d8c5503460f94a7346f/html5/thumbnails/37.jpg)
Acknowledgements
Richard Champlin Marcos de Lima Elizabeth ShpallLaurence Cooper Frank Marini John McMannisSimrit Parmar Chitra Hosing Nina ShahBorje Andersson Michael Andreeff Simon RobinsonSteven Kornblau Sergio Giralt Hong Yang Roy Jones Peter Thall Dongxia Xing Martin Korbling Paolo Anderlini William Decker Amin Alousi Issa Khouri Michael ThomasNaoto Ueno Jeffrey Molldrem Patrick ZweidelerPartow Kebriaei Muzaffar Qazilbash Tara SadeghiLaura Worth Demetri Petropoulos Indreshpal KaurMark Munsell Marcelo Fernandez-Viña Sufang LiJingjing Ng Ping Fu Jared BurksDoyle Bosque Lori Griffin Susan KellyGabriela Rondon Rima Saliba Sufira Kiran
Paul SimmonsNatalie Brouard
Funding NCI : R01- CA061508NCI : PO1- CA148600CPRIT: RP100469CPRIT: RP 100430CLL Global Research FoundHRSA: 234200737
Catherine BollardGianpietro Dotti
Ann LeenBarbara Savoldo
Mary HorowitzMary Eapen
Ian McNieceKrishna Komanduri